Advisors Preferred LLC Takes $1.08 Million Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Advisors Preferred LLC purchased a new position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 50,171 shares of the biopharmaceutical company's stock, valued at approximately $1,080,000.

Other hedge funds have also bought and sold shares of the company. GAMMA Investing LLC grew its holdings in Catalyst Pharmaceuticals by 62.1% during the 3rd quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company's stock valued at $35,000 after buying an additional 681 shares in the last quarter. nVerses Capital LLC purchased a new position in Catalyst Pharmaceuticals during the 3rd quarter valued at $50,000. Larson Financial Group LLC lifted its holdings in Catalyst Pharmaceuticals by 27,218.2% during the 3rd quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company's stock valued at $60,000 after buying an additional 2,994 shares in the last quarter. KBC Group NV boosted its holdings in shares of Catalyst Pharmaceuticals by 48.8% in the fourth quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company's stock valued at $98,000 after purchasing an additional 1,542 shares during the period. Finally, Thurston Springer Miller Herd & Titak Inc. bought a new stake in shares of Catalyst Pharmaceuticals in the fourth quarter valued at about $134,000. Hedge funds and other institutional investors own 79.22% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on CPRX. Bank of America reissued a "buy" rating and set a $30.00 target price on shares of Catalyst Pharmaceuticals in a research report on Thursday, January 9th. Truist Financial boosted their price target on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a "buy" rating in a report on Monday, November 11th. StockNews.com lowered Catalyst Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Saturday, January 11th. HC Wainwright raised their target price on shares of Catalyst Pharmaceuticals from $30.00 to $35.00 and gave the stock a "buy" rating in a research note on Friday, January 10th. Finally, Robert W. Baird assumed coverage on shares of Catalyst Pharmaceuticals in a report on Tuesday, February 4th. They issued an "outperform" rating and a $28.00 target price on the stock. Nine investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $32.25.

Insider Buying and Selling

In related news, insider Steve Miller sold 50,000 shares of Catalyst Pharmaceuticals stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $21.93, for a total transaction of $1,096,500.00. Following the sale, the insider now directly owns 686,996 shares in the company, valued at $15,065,822.28. The trade was a 6.78 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Molly Harper sold 17,500 shares of the business's stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $22.00, for a total transaction of $385,000.00. The disclosure for this sale can be found here. Insiders have sold 79,500 shares of company stock valued at $1,754,140 in the last quarter. Company insiders own 11.00% of the company's stock.

Catalyst Pharmaceuticals Trading Up 0.5 %

Shares of Catalyst Pharmaceuticals stock traded up $0.12 during trading hours on Wednesday, reaching $22.70. The stock had a trading volume of 808,063 shares, compared to its average volume of 1,313,706. The firm has a market capitalization of $2.71 billion, a price-to-earnings ratio of 19.24, a P/E/G ratio of 3.46 and a beta of 0.80. The firm has a 50 day simple moving average of $22.12 and a two-hundred day simple moving average of $21.04. Catalyst Pharmaceuticals, Inc. has a 1 year low of $13.13 and a 1 year high of $24.64.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.